Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

IBO

Impact BioMedical Inc

Jun 18 • 04:00PM ET

0.5022

-0.0748 -12.96 %

Healthcare • Biotechnology • USA • Micro • AMEX

Peers: ANVS EXOZ FBIO IBIO ICCC IMA IMMP MCRB PLRX XBIT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.27	Insider Own	0.46%	Shs Outstand	107.82M	Perf Week	-10.32%
Market Cap	54.15M	Forward P/E	-	EPS next Y	-	Insider Trans	-34.04%	Shs Float	107.32M	Perf Month	-6.71%
Enterprise Value	57.38M	PEG	-	EPS next Q	-	Inst Own	3.45%	Short Float	0.70%	Perf Quarter	8.47%
Income	-12.86M	P/S	1353.63	EPS this Y	-	Inst Trans	3.43%	Short Ratio	3.24	Perf Half Y	13.36%
Sales	0.04M	P/B	4.72	EPS next Y	-	ROA	-69.25%	Short Interest	0.75M	Perf YTD	-0.55%
Book/sh	0.11	P/C	2707.27	EPS next 5Y	-	ROE	-168.00%	52W High	1.95 -74.25%	Perf Year	16.14%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	15.09% -48.53%	ROIC	-112.16%	52W Low	0.36 38.69%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-3953.85%	Volatility	8.66% 8.51%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1434.38	EPS Y/Y TTM	41.51%	Oper. Margin	-14225.64%	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.19	Sales Y/Y TTM	-	Profit Margin	-32969.23%	RSI (14)	39.51	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	79.81%	SMA20	-7.75%	Beta	2.45	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-16.29%	Rel Volume	0.46	Prev Close	0.58
Employees	8	LT Debt/Eq	0.00	Earnings	-	SMA200	-9.22%	Avg Volume	231.34K	Price	0.50
IPO	Sep 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	105,545	Change	-12.96%

Apr-03-26 01:52PM	Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans (GlobeNewswire)
Mar-04-26 11:38PM	Impact Biomedical (IBO) Stock Jumps Over 86% After Hours - Here's Why (Benzinga) +55.46%
Aug-18-25 08:30AM	Impact Biomedical Inc (IBO) Announces 3F US Patent Issue (GlobeNewswire)
Jun-23-25 07:52AM	Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger (GlobeNewswire) +344.63%
Mar-21-25 02:38PM	Impact Biomedical Inc. Announcement Stock Activity/Pricing (GlobeNewswire) +138.46%
08:30AM	Loading…
Feb-26-25 08:30AM	Impact Biomedical Inc. Announces Acquisition of Celios , Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality (GlobeNewswire)
08:30AM	DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth (GlobeNewswire)
Jan-23-25 04:30PM	Impact BioMedical Inc. to Present at The Microcap Conference (GlobeNewswire) +12.68%
Nov-19-24 08:00AM	Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision (GlobeNewswire) -17.44%
Nov-18-24 07:00AM	Impact BioMedical Inc. (NYSEAmerican: IBO): Targeting Chronic Diseases with Patented Breakthroughs (News Direct)
Nov-11-24 07:30AM	Positioned for Growth: Impact BioMedical Inc.'s (NYSEAmerican: IBO) Push into Cancer and Immune Health (News Direct) -9.31%
Oct-15-24 06:00AM	Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease (GlobeNewswire) +19.20%
Oct-07-24 08:30AM	Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates (GlobeNewswire) +5.50%
Sep-26-24 08:30AM	Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue (GlobeNewswire)
Sep-23-24 08:00AM	Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth (GlobeNewswire) +6.87%
11:29AM	Loading…
Sep-17-24 11:29AM	Impact BioMedical Inc. Announces the Closing of its Initial Public Offering (GlobeNewswire) -13.06%
Sep-16-24 04:26PM	DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value (GlobeNewswire)
10:24AM	Impact BioMedical Inc. Announces Pricing of Initial Public Offering (GlobeNewswire)

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.

J.D.Mr. Frank D. Heuszel Esq.

CFOMr. Todd D. Macko CPA

Chief Operating OfficerMr. Mark J. Suseck

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DSS INC.	Stockholder	Apr 22 '26	Proposed Sale	0.72	31,939,778	23,064,209		Apr 29 06:08 PM
Macko Todd D	Chief Financial Officer	Mar 27 '26	Sale	0.56	43,400	24,369	155,122	Mar 30 09:06 PM
Macko Todd D	Chief Financial Officer	Mar 25 '26	Sale	0.60	1,600	961	198,122	Mar 30 09:06 PM
Grady Jason	Director	Mar 23 '26	Sale	0.65	50,000	32,505	250,182	Mar 25 07:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IBO

Impact BioMedical Inc

Upgrade your Finviz experience